Want to see IN:DIVISLAB full AI Analyst Report?
DIVISLAB Stock Chart & Stats
₹7246.65
₹165.50(2.28%)
At close: 4:00 PM EDT
₹7246.65
₹165.50(2.28%)
Day’s Range― - ―
52-Week Range₹5,637.50 - ₹8,670.50
Previous CloseN/A
Volume544.67K
Average Volume (3M)6.36K
Market Cap
₹2.27T
Enterprise Value₹1.54M
Total Cash (Recent Filing)₹32.33B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)77.1
Beta0.82
Next Earnings
Nov 09, 2026EPS Estimate
30.1Next Dividend Ex-DateN/A
Dividend Yield0.35%
Share Statistics
EPS (TTM)110.22
Shares Outstanding265,468,570
10 Day Avg. Volume6,055
30 Day Avg. Volume6,356
Financial Highlights & Ratios
PEG Ratio3.57
Price to Book (P/B)9.42
Price to Sales (P/S)14.95
P/FCF Ratio317.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹8,567.50Price Target Upside18.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)123.91
Revenue Forecast (FY)₹125.69B
Bulls Say, Bears Say
Bulls Say
Fortress Balance SheetNegligible leverage and a steadily expanding equity base give Divi’s substantial financial resilience. This supports continued investment in manufacturing capacity, regulatory compliance and process development without material balance-sheet strain.
Revenue And Earnings GrowthThe recovery in revenue and substantial earnings growth indicate improving demand and operating scale across APIs and custom manufacturing. A larger earnings base can strengthen the company’s ability to fund capacity and sustain customer programs.
Improving Operating Cash GenerationStrong recent operating cash generation improves internal funding capacity for capital expenditure, process development and working capital. This reduces reliance on external financing and supports resilience through API demand cycles.
Bears Say
Margin NormalizationProfitability remains healthy but has retreated materially from prior peaks, indicating that some earlier pricing, mix or utilization benefits were not fully structural. Sustained margin normalization could limit earnings growth even if revenue expands.
Uneven Free Cash Flow ConversionOperating cash flow has improved, but free cash flow remains volatile relative to earnings, reflecting reinvestment, capital expenditure or working-capital swings. This variability can constrain consistently distributable cash and complicate long-term planning.
Lower Returns On EquityFalling ROE while the equity base compounds suggests incremental capital is generating lower returns than during the strongest period. If this persists, it may signal weaker profitability efficiency or less attractive economics for future expansion.
Divi's Laboratories Limited News
DIVISLAB FAQ
What was Divi's Laboratories Limited’s price range in the past 12 months?
Divi's Laboratories Limited lowest stock price was ₹5637.50 and its highest was ₹8670.50 in the past 12 months.
What is Divi's Laboratories Limited’s market cap?
Divi's Laboratories Limited’s market cap is ₹2.27T.
When is Divi's Laboratories Limited’s upcoming earnings report date?
Divi's Laboratories Limited’s upcoming earnings report date is Nov 09, 2026 which is in 76 days.
How were Divi's Laboratories Limited’s earnings last quarter?
Divi's Laboratories Limited released its earnings results on Aug 01, 2026. The company reported ₹33.95 earnings per share for the quarter, beating the consensus estimate of ₹25.392 by ₹8.558.
Is Divi's Laboratories Limited overvalued?
According to Wall Street analysts Divi's Laboratories Limited’s price is currently Undervalued.
Does Divi's Laboratories Limited pay dividends?
Divi's Laboratories Limited pays a Annually dividend of ₹30 which represents an annual dividend yield of 0.35%. See more information on Divi's Laboratories Limited dividends here
What is Divi's Laboratories Limited’s EPS estimate?
Divi's Laboratories Limited’s EPS estimate is 30.1.
How many shares outstanding does Divi's Laboratories Limited have?
Divi's Laboratories Limited has 265,468,570 shares outstanding.
What happened to Divi's Laboratories Limited’s price movement after its last earnings report?
Divi's Laboratories Limited reported an EPS of ₹33.95 in its last earnings report, beating expectations of ₹25.392. Following the earnings report the stock price went up 4.889%.
Which hedge fund is a major shareholder of Divi's Laboratories Limited?
Currently, no hedge funds are holding shares in IN:DIVISLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Divi's Laboratories Limited
Divi's Laboratories Limited, established in 1990 and based in Hyderabad, India, operates globally in the production and distribution of generic active pharmaceutical ingredients (APIs), intermediate chemicals, and nutraceuticals. The company's market footprint encompasses India, the United States, Asia, Europe, and other international regions. In addition to its core product lines, Divi's offers bespoke synthesis services for APIs and intermediates. It also provides a diverse range of carotenoids and markets various vitamins, catering to the nutritional, pharmaceutical, food and beverage, and animal feed industries. The firm was formerly known as Divi's Research Center before rebranding to Divi's Laboratories Limited in 1994.
DIVISLAB Stock 12 Month Forecast
Average Price Target
₹8,567.50
▲(18.23% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Granules India Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―








